New cancer vaccine shows 88% prevention in mice
New cancer vaccine prevents up to 88% of aggressive cancers in mice.
Why it matters
- Potential breakthrough in cancer treatment.
- Targets aggressive and difficult-to-treat cancers.
- Uses nanoparticles to train the immune system.
By the numbers
- 88% prevention rate in mice.
- 100% tumor rejection in vaccinated mice with multiple peptides.
- Tested on melanoma, pancreatic cancer, and TNBC.
The big picture
- Vaccine combines two immune-stimulating molecules in nanoparticles.
- Enhances both innate and adaptive immune responses.
- Shows long-term immune memory in mice.
What they're saying
- Some express skepticism about real-world application.
- Concerns about commercialization and potential suppression.
- Personal anecdotes about the impact of cancer.
Caveats
- Study conducted in mice, not humans.
- Further research needed to confirm findings in humans.
What’s next
- Human trials needed to validate the vaccine's effectiveness.
- Potential for use as both a treatment and preventive measure.
- Startup NanoVax Therapeutics formed to pursue translational efforts.